Precision-Engineered Bismuth-Based Nanocomposites as Next-Generation Biocompatible Contrast Agents: A Rigorous Multi-Scale Theoretical, Computational, and Translational Framework

Background. Iodinated contrast agents (ICAs) for computed tomography (CT) and gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) remain the clinical standard, yet impose documented risks---contrast-induced acute kidney injury (CI-AKI) and nephrogenic systemic fibrosis (NSF)---particularly in renally compromised patients.Objective. This perspective establishes a rigorous, multi-scale theoretical and computational framework to evaluate bismuth-based nanocomposites (Bi₂S₃, Bi/Bi₂O₃) as precision-engineered alternatives, integrating first-principles X-ray physics, advanced three-compartment pharmacokinetics (PK), colloidal stability theory, and the Proposed Integrative Design--Validation--Translation (PI-DVT) pipeline.Methods. A systematic review of >70 peer-reviewed studies (2006--2025) was conducted. Geant4 Monte Carlo and COMSOL Multiphysics simulations were parameterized from established literature benchmarks. Sensitivity analyses (±20% parameter perturbations) and Monte Carlo uncertainty propagation quantify model robustness. The three-compartment PK model explicitly accounts for reticuloendothelial system (RES) sequestration, protein corona dynamics, and sigmoidal renal elimination gated on hydrodynamic diameter.Results. Simulations forecast that Bi₂S₃ nanoparticles (3--6 nm, PEGylated) yield X-ray mass attenuation coefficients of ~5.74 cm²/g at 100 keV---approximately 3× that of iodine---and Hounsfield unit (HU) enhancements of 350 at 3 mg/mL. The PK model predicts >85% renal clearance within 24 hours under idealized conditions, with RES retention <2% under optimized PEG densities (0.8 chains/nm², 2--5 kDa); the 95% credible clearance interval is 83.2--92.4%. These are theoretical projections from analogous systems; no Bi₂S₃-specific human PK data exist. Recent (2025) ultrasmall Bi/Bi₂O₃ nanoparticles corroborate >2-fold attenuation and 95% cell viability in vitro. Radiosensitizer enhancement ratios (SER) up to 4.93 and combined radiotherapy--chemodynamic therapy (RT-CDT) synergy projecting >70% tumor regression in murine models substantiate theranostic potential.Conclusions. Bismuth-based nanocomposites present a physically and chemically coherent rationale as alternatives to conventional agents. All safety, efficacy, and cost projections are computational predictions extrapolated from first principles and analogous nanomaterial data; they must not be interpreted as clinical evidence. Empirical validation through staged in vitro/in vivo studies and Phase I clinical trials is the critical next milestone, guided by the PI-DVT framework. No clinical conclusions should be drawn from computational predictions alone.